Menopause Testosterone Caution on Bioidentical Formulas

Bioidentical Testosterone for Menopause: Experts Issue Caution on Compounded Formulas

A recent position statement from a leading Latin American medical society calls for restraint in prescribing testosterone to menopausal women, specifically warning against the use of popular compounded “bioidentical” formulas. The Latin American Association of Gynecological Endocrinology (ALEG) analyzed two decades of evidence to provide guidance for a region where, they note, prescribing is often unregulated and based on products made for men.

Latin American Experts Define a Narrow Role for Testosterone

Led by Dr. Sara Pilnik of the Hospital Italiano de Buenos Aires, the ALEG panel gave its strongest recommendation (Grade A) to a single, specific use: testosterone therapy for postmenopausal women with hypoactive sexual desire disorder. HSDD is a clinical diagnosis of distressing low libido that persists despite adequate estrogen therapy and requires a formal evaluation of physical, relational, and psychological factors. The group explicitly states that systemic dehydroepiandrosterone (DHEA), an over-the-counter androgen precursor, is not advised for treating sexual symptoms. Vaginal DHEA is only approved for local symptoms of genitourinary syndrome, like dryness and pain.

This clarification addresses a significant gap. In many Latin American countries, the authors report, no androgen products are formally approved for women. This leads clinicians to prescribe medications formulated and dosed for men or turn to custom-made, non-standardized compounded products.

Compounded Bioidentical Testosterone Poses Specific Risks

The position statement draws a critical distinction between pharmaceutical-grade transdermal testosterone gels or patches and compounded subcutaneous pellets marketed as “bioidentical.” The panel does not recommend these pellets, citing a “Grade C: Low” evidence level for this guidance. The core issue is one of control and consistency.

While “bioidentical” refers to a hormone’s molecular structure matching the human form, the term is not synonymous with “safe” or “regulated.” Compounding pharmacies create custom doses, and subcutaneous pellets release testosterone over months in an uncontrolled manner. This makes it difficult to adjust or stop the dose quickly if side effects like acne, hair loss, or voice changes occur. More concerningly, the panel notes these delivery methods carry “risks of supraphysiological dosing”—levels that exceed what the ovaries produced before menopause. Long-term effects of sustained high androgen levels in women are not fully understood.

Monitoring Therapy Means Checking Levels, Not Chasing a Number

The ALEG guidelines upend a common assumption about hormone therapy: that treatment requires achieving a specific “optimal” blood level. The panel states clearly that routine measurement of testosterone or other androgens is not recommended for diagnosing HSDD. Instead, the clinical diagnosis is paramount.

However, checking a baseline testosterone level before starting therapy is advised to rule out already elevated concentrations. Once treatment begins, the goal of monitoring—within 3 to 6 weeks of starting—is to ensure the dose keeps testosterone within the normal premenopausal physiological range. This practice aims to provide symptom relief while minimizing virilizing side effects. It represents a shift from chasing an arbitrary lab value to using the test as a safety check.

Applying Evidence to Clinical Practice and Patient Choice

For women considering testosterone, this position statement provides a framework for informed discussion. First, a comprehensive assessment for HSDD is essential, which may involve exploring other contributing factors like relationship stress, depression, or other medical conditions. Non-hormonal options, such as cognitive behavioral therapy, should also be part of the conversation.

If testosterone is appropriate, patients should seek a transdermal formulation with a known, consistent dose. They must understand the therapy is off-label. Crucially, they should be wary of clinics promoting compounded testosterone pellets as a superior or more “natural” bioidentical option, as these lack rigorous safety data and pose unique risks. The panel’s stance aligns with other recent guidance, such as the New Latin American Testosterone Guidelines, which similarly emphasize evidence-based, cautious use.

The ALEG statement underscores that managing menopause, including challenges like low libido, requires strategies grounded in strong evidence. While testosterone can be a powerful tool for some, its application must be precise, monitored, and based on pharmaceutical-grade products, not unregulated compounds.

Sources:
https://pubmed.ncbi.nlm.nih.gov/40919649/
https://pubmed.ncbi.nlm.nih.gov/40109076/
https://pubmed.ncbi.nlm.nih.gov/38980733/